The work from this study provides support for blockade of CCN2 expression or activity as a feasible therapeutic option for pulmonary fibrosis and pulmonary hypertension such as that in SSc and other diseases where CCN2 is overexpressed and plays a key role in pathogenesis. The gene discussed is CCN2; the disease is pulmonary arterial hypertension.